ArticleEuropean journal of nuclear medicine and molecular imaging2022
Synthesis, preclinical evaluation, and first-in-human study of Al
Article in European journal of nuclear medicine and molecular imaging, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 11 citations in OpenAlex.
- Evaluation of the safety and efficacy ofEuropean radiology experimental · 2026Trial
- [Cancer imaging : the official publication of the International Cancer Imaging Society · 2026Article
- A Preclinical Study of a PSMA Ligand-Based Dual-Modality Probe for Radical Prostatectomy.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Comparison ofEuropean journal of nuclear medicine and molecular imaging · 2025Article
- Preclinical and clinical evaluation of [Scientific reports · 2025Article
- Recent advancements in new tracers from first-in-human studies.Annals of nuclear medicine · 2024Review
- Molecular Eye: A System for Precise Diagnosis and Treatment of Major Clinical Diseases Based on Molecular Probe Technology.Chemical & biomedical imaging · 2024Review
- Optimized TherapeuticPharmaceuticals (Basel, Switzerland) · 2022Article
- Blocking Studies to Evaluate Receptor-Specific Radioligand Binding in the CAM Model by PET and MR Imaging.Cancers · 2022Article
- State-of-the-art of nuclear medicine and molecular imaging in China: after the first 66 years (1956-2022).European journal of nuclear medicine and molecular imaging · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo investigate the potential of a novel Al
methodsAl
resultQualified Al
conclusionThe novel qualified PSMA-targeted radiotracer Al
trial registrationChinese Clinical trial registry ChiCTR2100053507, Registered 23 November 2021, retrospectively registered.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.